Michael Boswell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8211306/publications.pdf

Version: 2024-02-01

1039406 1281420 2,341 13 9 11 citations h-index g-index papers 25 25 25 5152 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity. Cell Reports Medicine, 2022, 3, 100510.	3.3	51
2	T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature, 2022, 603, 488-492.	13.7	430
3	Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa. International Journal of Infectious Diseases, 2022, 116, 38-42.	1.5	301
4	Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern. Cell Reports Medicine, 2022, 3, 100535.	3.3	31
5	SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals. Cell Host and Microbe, 2022, 30, 880-886.e4.	5.1	80
6	Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants. Journal of Virology, 2022, 96, .	1.5	7
7	Effect of antimicrobial peptides on planktonic growth, biofilm formation and biofilm-derived bacterial viability of Streptococcus pneumoniae. Southern African Journal of Infectious Diseases, 2021, 36, 226.	0.3	1
8	Skin and mucosal manifestations of an AIDS-related systemic mycosis. Southern African Journal of HIV Medicine, 2021, 22, 1198.	0.3	0
9	SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nature Medicine, 2021, 27, 622-625.	15.2	984
10	Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). New England Journal of Medicine, 2021, 384, 2161-2163.	13.9	111
11	TRIM22 genotype is not associated with markers of disease progression in children with HIV-1 infection. Aids, 2021, Publish Ahead of Print, 2445-2450.	1.0	0
12	A17â€∱The effect of intra-host evolution of HIV-2 capsid on disease progression. Virus Evolution, 2019, 5, .	2.2	0
13	Delayed disease progression in HIV-2: the importance of TRIM5α and the retroviral capsid. Clinical and Experimental Immunology, 2019, 196, 305-317.	1.1	11